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Abstract
Background Immunoglobulin A nephritis (IgAN) is the
most common primary glomerulonephritis worldwide. It is
caused by accumulation of IgA1-containing immune com-
plexes in the kidney resulting in renal failure, which is
thought to be due to altered glycosylation of IgA with a
decrease of 2–3-sialylated galactosides (NeuAcα2-3Gal).
Purpose The purpose of this study was to analyze whether
altered glycosylation of IgAwould lead to an altered binding
to galectin-8, an endogenous lectin with strong affinity for 2–
3-sialylated galactosides. Galectins are a family of β-
galactoside-binding proteins; by binding various glycopro-
teins, they play important roles in the regulation of cellular
functions in inflammation and immunity. Hence, an altered
binding of IgA to galectin-8 could lead to pathologic immune
functions, such as glomerulonephritis.
Methods Affinity chromatography of serum glycoproteins
on the human sialogalactoside-binding lectin galectin-8N
permitted quantitation of bound and unbound fractions,
including IgA.
Results Analysis of ∼100 IgA nephritis sera showed that the
galectin-8N unbound fraction of IgA increased compared to
∼100 controls, consistent with the known loss of galactosy-
lation.Asubgroupof∼15%oftheIgANpatientshadaratioof
galectin-8bound/unboundIgA<0.09,notfoundforanyofthe
controls. Unexpectedly, the galectin-8N-binding fraction of
serum glycoproteins other than IgA increased in the sera of
IgAN patients but not in controls, suggesting a previously
unrecognized change in this disease.
Conclusion This is the first study that relates a galectin, an
endogenous lectin family, to IgA nephritis and thus should





Immunoglobulin A nephritis (IgAN) was first described in
1968 by Berger and colleagues; in an immunofluorescence
study of renal biopsies from an unknown form of
glomerulonephritis, mesangial deposits with IgA as their
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deposits in renal biopsies is still the only means to diagnose
what is now recognized to be the most common glomer-
ulonephritis worldwide, affecting 1.3% of the population
[2], with 20–40% developing renal end stage failure within
20 years [3]. Population studies showing familiar clustering
and geographical variations [4–6] and genetic studies [2, 7,
8] suggest a strongly inherited predisposition for IgAN,
although no causative mechanism has been identified.
Considerable evidence suggests that the IgA deposited in
the kidney has originated from circulating undergalactosy-
lated IgA1 complexes [9–12]. Each IgA1 heavy chain
contains up to six O-linked glycans in the hinge region
between the CH1 and CH2 domains (Fig. 1). In normal
IgA1, complete core-1 O-glycans like NeuAcα2,3Galβ1-
3GalNAc linked to Ser or Thr are common (top glycan in
Fig. 1), whereas in IgA nephritis IgA1, the O-glycans tend
to lack the galactose residue as in GalNAc-Ser(Thr) or
NeuAcα2,6GalNAc-Ser(Thr) (two bottom glycans in
Fig. 1). In IgA nephritis, IgA-producing B cells have a
glycosyltransferase imbalance in which a β1,3 galactosyl-
transferase and/or its chaperone Cosmc is downregulated
[13, 14], resulting in decreased formation of Galβ1-
3GalNAc (second glycan in Fig. 1), and increased activity
of a α2,6 sialyltransferase resulting in increased addition of
NeuAcα2,6 to the GalNAc (bottom glycan of Fig. 1) that
also prevents further addition of Galβ1,3; the absent
galactose in turn prevents further addition of NeuAcα2,3.
Genetic variants of the β1,3 galactosyltransferase
(C1GalT1) and its chaperone Cosmc with decreased
activity and the α2,6 sialyltransferase with increased
activity [15] may contribute to this and thereby predispose
to IgA nephritis, but there may also be other non-genetic
mechanisms for the aberrant glycosylation of IgA.
Evidence from many studies suggest that the abnormal
O-glycosylation of IgA1 found in IgAN patients plays a
central role in the pathogenesis of the disease [11, 14, 16,
17], but the mechanism remains unclear [18, 19]. Altered
aggregation, altered interaction with mesangial cells in the
kidney, altered binding to IgA receptors, and IgG-specific
recognition for exposed GalNAc all have been suggested to
contribute either to increased deposition of IgA-containing
complexes in the kidney or decreased clearance in the liver.
Altered interaction with a carbohydrate-binding protein, a
lectin, would be a reasonable hypothesis to explain the
changed function of undergalactosylated IgA. Snail lectins
specifically binding the exposed GalNAc residues have
been used diagnostically for detection in patients [20, 21],
but there have been few studies on the relationship of IgA
glycosylation and the binding of endogenous lectins that
might affect its function.
Galectin-8 is a good candidate for such a relationship.
Galectin-8 contains two canonical galectin carbohydrate
recognition domains (CRD) joined by a linker [22]. Like
other galectin CRDs, they bind β-galactosides, but the N-
terminal CRD of galectin-8 (galectin-8N) has a particularly
high affinity if the β-galactoside is 2–3-sialylated and also
bound with a 1–3 linkage to the next sugar, as found in
NeuAcα2,3Galβ1,3GalNAc (top glycan of Fig. 1)[ 23, 24],
and is the only mammalian galectin with high affinity for
IgA [25]. In addition, a NeuAcα2,6 attached to the GalNAc
residue strongly reduces affinity for galectin-8N [24]. This
predicts that the carbohydrate structural and enzymatic
changes in IgA nephritis patients described in the previous
paragraph should reduce the binding of IgA1 to galectin-
8N. In addition to this, galectin-8 exerts several immuno-
regulatory functions, playing a critical role in shaping the
immune response and regulating inflammation [26, 27].
Depending on the context, galectin-8 can provide both
inhibitory and stimulatory effects on immune cell adhesion
[28, 29], in addition to induction of immune cell growth
and apoptosis [30, 31]. In contrast to cytokines, galectins
do not bind specific individual receptors, but rather “sense”
the glycocode expressed on the cell surface of a cell. The
dual activities of galectin-8 may therefore reflect a
controlled regulation of glycosylation, e.g., activation and
differentiation of immune cells but could also be a
consequence of disease-associated glycosylation changes,
e.g., immune escape mechanisms in which cell surface
glycans can be altered to avoid immune recognition. For
instance, we have recently found that sera from metastatic
breast cancer patients contain two to three times more
Fig. 1 Simplified schematic of pathological O-glycosylation changes
of IgA1 in IgAN and predicted binding of galectin-8. The two top
O-glycans NeuAcα2,3Galβ1,3GalNAcα and Galβ1,3GalNAc are
predominant (30–40% each) in IgA1 of normal sera [35], whereas
the bottom two, GalNAcα and Neuα2,6GalNAcα, increase in IgA1
from IgAN patients, due to decreased activity of the galactosyltrans-
ferase adding the Galβ1,3 (black circle in top two glycans) and
increased activity of the sialyltransferase adding the NeuAcα2,6
(vertical diamond in bottom glycan) to GalNAc (open square).
Galectin-8N binds the top O-glycan with high affinity, but not the
others [24]. The NeuAcα2,6 sialyltransferase may also act on the top
structure to make NeuAcα2,3Galβ1,3(NeuAcα2,6)GalNAc, but also
this structure has strongly reduced affinity for galectin-8N [24]. Thus,
galectin-8N binding of IgA1 is expected to decrease in IgAN
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result in altered function relevant for the disease [32]. In
relation to the present study, using an autoimmune model of
rheumatoid arthritis, galectin-8 has been shown to be
trapped in the inflamed joint prohibiting it from inducing
apoptosis in inflammatory cells resulting in an enhanced
inflammatory response [33]. In light of these considera-
tions, analyzing galectin-8 ligands in sera from IgAN
patients has a great potential to not only detect the known
alterations in glycosylation of the disease but may also
suggest a pathophysiologically relevant function since these
ligands most likely will encounter this galectin in tissue cells.
Material and Methods
Production of Recombinant Galectins
Recombinant galectin-8N and the mutant Q47A were
produced in Escherichia coli BL21 Star (Invitrogen) in 1-
l Luria–Bertani medium and stirred at 200 rpm at 37°C
overnight. The expression of galectin-8N was induced by
isopropyl-β-D-1-thiogalactoside, and the culture was further
stirred for 3 h. The bacteria were collected by centrifuga-
tion, and the pellet was then suspended in phosphate-
buffered saline (PBS; pH 7.2) containing 4-mM β-
mercaptoethanol and 2-mM EDTA (MEPBS) and sonicated
on ice for 1 min, 12 times. After centrifugation, the protein
containing supernatant was run on a lactosyl-sepharose
column. Galectin-8N was then eluted with MEPBS con-
taining 150-mM lactose. Lastly, lactose was eliminated
from galectin-8N with Centricon® Plus-70 Centrifugal
Filter Units (Millipore).
Serum Samples
Serum samples from 20 healthy volunteers (average age 45,
ratio male/female 60:40), 100 IgAN patients (average age
41, ratio male/female 76:24), and 92 patients with other
forms of glomerulonephritis (average age 55, ratio male/
female 38:58) (selected as the first non-IgAN sample in the
bio-bank taken after the respective IgAN sample) were
collected and stored as previously described [25].
Patients and Controls
T h ep a t i e n t sa n dt h ec o n t r o l si nt h i ss t u d yw e r ea l l
participants in a long-term prospective study of glomerular
diseases conducted at the Department of Nephrology, Lund
University Hospital, Sweden. Serum samples were taken at
time of kidney biopsy. Presenting symptoms were most
often hematuria. After approval by the ethical committee at
Lund University (LU 47-02), we obtained written informed
consent from patients with biopsy-proven IgAN, diagnosed
between February 1992 and November 2003. The morpho-
logical diagnoses were established by evaluation of
representative percutaneous renal biopsy specimens by both
light microscopy and direct immunofluorescence. The
diagnosis of IgAN was based on the finding of IgA as the
dominant or co-dominant immunoglobulin in a mesangial
distribution pattern.
Out of the 87 patients included in the cohort, 30 (ratio
male/female 28:2) patients reached end stage renal disease
(ESRD), 3 (ratio male/female 2:1) died, and 6 (ratio male/
female 4:2) patients were lost from follow-up. All other
patients were followed up to the last planned visit in 2009.
The number, age, gender, and baseline data of patients are
presented in Table I.
Neuraminidase Treatment of Sera
One-milliliter sera from healthy subject H2 were treated
with 0.5 μmol of neuraminidase (sialidase) from Vibrio
cholerae (Roche) in 10-mM sodium acetate buffer, pH=5,
for 1 h at 37°C.
Galectin Affinity Chromatography
Galectin-8N and galectin-8 Q47A were coupled to 1-ml
NHS-activated Hi-Trap affinity columns (Amersham Bio-
Table I Baseline clinical characteristics (January 1990) of the studied
IgA nephritis patients with or without ESRD
ESRD No ESRD
Number (M/F) 30 (28/2) 60 (48/12)
Age (years) 38 (13) 34 (26)
Sys Bp 160 (40) 135 (30)
Dias Bp 95 (24) 80 (20)
S-Crea (μmol) 142 (172) 90 (38)
S-albumin (g/l) 31 (11) 37 (6)
Albuminuria (mg/mmol) 134 (170) 26 (91)
CRP (mg/l) 5 (1) 5 (10)
Glomerulosclerosis (%) 26.5 (41.4) 9.1 (21.9)
Severe fibrosis, n (%) 20 (66.7%) 8 (14.3%)
Follow-up (months) 59 (65) 142 (88)
IgA (mg/l) 3.1 (1.28) 3.3 (1.7)
Gal 8 3 (2.5) 3.6 (1.1)
Gal 8 bound 0.72 (0.58) 0.77 (0.93)
Gal 8 unbound 2.4 (1.32) 2.42 (1.84)
Gal 8 bound IgA omitted 2.19 (1.9) 2.5 (1.64)
Ratio bound/unbound 0.31 (0.32) 0.29 (0.53)
Numbers represent median and (inter-quartile range)
Sys Bp systolic blood pressure, Dias Bp diastolic blood pressure, S-
crea serum creatinine, CRP C-reactive protein
248 J Clin Immunol (2012) 32:246–255sciences) as described in [25]. Sample loading, washing,
and elution were carried out as described previously [25],
protein concentrations determined with the Bio-Rad protein
assay, and fractions stored at −20°C until further analysis.
Columns were used for approximately 20 chromatographed
sera. Within this limit, there was <4% variation in the
bound protein amount, when the same serum was
rechromatographed, as shown for 12 different sera of
IgAN patients and controls. For some sera, the unbound
fraction was chromatographed a second time on the same
reconstituted column, but no more proteins bound (not
shown), demonstrating that the column was not over-
loaded, and bound proteins not overlooked because of
competition with other proteins. In some cases, the gel
material of finished columns was analyzed by SDS-PAGE
for possible protein retention after lactose elution, as
described previously [25].
SDS-PAGE
Serum ligands were analyzed by one-dimensional 4–20%
SDS-PAGE, all as described previously [25].
IgA Measurements
IgA content of sera (diluted 1/10 in PBS) or pooled
galectin-8N binding fractions from 98 IgAN patients, 20
healthy donors, and 76 controls with IgAN symptoms were
analyzed with nephelometry, IMMAGE 800 (Beckman
Coulter) using a low concentration Immunoglobulin A
Reagent kit (Beckman Coulter).
LC–MS/MS
Four samples (H2, K2, P2 and P4) of galectin-8N bound
serum glycoproteins were analyzed by LC–MS/MS of pooled
tryptic peptides to identify major protein components and
estimate their relative abundance as described in Electronic
Supplementary Material—Supplementary methods.
Results
Binding of Serum Glycoproteins to Galectin-8N
The binding of serum glycoproteins to galectin-8N was
analyzed by affinity chromatography (first trace in Fig. 2).
This resulted in sharp separation between an unbound
flow through fraction and a bound fraction that could be
eluted with lactose. The main components of the bound
f r a c t i o na r eg i v e ni nF i g .3a, as determined previously
by MALDI-TOF MS and confirmed by western blotting
[25].
A deeper proteomics characterization by LC–MS/MS of
pooled tryptic peptides from the bound fraction of four
samples revealed over 100 proteins (Table SII). Their
concentrations were estimated from the MS data and the
percentages in the galectin-8N bound fraction by comparing
with known total concentrations in serum (Table SIII). For
some proteins, the percentage in the bound fraction was very
low, and they are likely contaminants from the unbound
fraction. Using albumin as a marker for this (0.3% in bound
fraction) and giving a margin for the variability of MS signal
fordifferentprotein(asdiscussedinElectronic Supplementary
Material—Supplementary methods), we defined protein with
<2% in bound fraction as non-binding, proteins >10% in the
bound fraction as clear significant galectin-8N binders, and
an intermediate group with 2–10% in the bound fraction as
likely binders but at a low level.
The group of clear significant galectin-8N bound proteins
(>10%) included as major components and in agreement
with Fig. 3a, IgA1, haptoglobin, α-2-macroglobulin, and
hemopexin (Fig. 3b), but also lower levels of inter-alpha-
trypsin inhibitor, orosomucuid, and a few other proteins
(Table SIII). These are included in the group “Others” in
Fig. 3b, with low binders (2–10%) such as apolipoproteins,
protease inhibitors, IgM, and some more. The non-binders
(<2%) included among major serum glycoproteins, trans-
ferrin, complement C3, IgG, and IgA2. Thus, galectin-8N
binding appears specific for IgA1 among immunoglobulins,
with a possible lower binding to IgM. This is in contrast to,
for example, galectin-1 where IgM is one of its major
serum ligands [32].
The analysis of multiple bound fractions by SDS-
PAGE (lanes marked B in Fig. 3c)a g r e e dw i t ht h e
results described above for a wider range of samples,
including the rough quantitation, for example, sample
Fig. 2 Affinity chromatography of untreated or 2,3-neuraminidase-
treated serum on immobilized human galectin-8N. Chromatograms of
serum from a healthy individual treated with specific neuraminidase
(NA) or untreated (UT) and subjected to affinity chromatography with
immobilized galectin-8N or the galectin-8 Q47A mutant, deficient in
binding to sialylated galactosides. The protein concentration of each
fraction (0.2 or 1 ml) is given on the Y-axis. Elution with lactose
(150 mM) started after washing with 32-ml PBS (arrow heads). Each
chromatogram has been moved for clarity by +0.1 on the Y-axis and
by +5 on the X-axis
J Clin Immunol (2012) 32:246–255 249P2 shows high haptoglobin both in panels b and c of
Fig. 3. The main visible components of unbound fractions
(lanes marked UB in Fig. 3c) were albumin, IgG, and
transferrin.
Galectin-8N did not bind any glycoproteins from serum
treated with neuraminidase (second trace in Fig. 2).
Moreover, the Q47A mutant of galectin-8, which has a
decreased affinity for sialylated glycans [24, 34], bound
much less serum glycoproteins (about 0.5 mg/ml) (third
trace in Fig. 2). This shows that binding of galectin-8N to
serum glycoproteins depends on the presence of 2–3-
sialylated galactosides. This is in contrast to galectin-1
and galectin-3, for which neuraminidase treatment of serum
gives increased binding (unpublished). The Q47A mutant
bound slightly more glycoproteins from neuraminidase-
treated serum (trace 4 in Fig. 2), which may be explained
by its increased affinity for some non-sialylated galactosides
[23, 24, 34].
Large Increase of Galectin-8N-Binding Serum
Glycoproteins in IgAN Patients
Serum samples were collected from 192 patients at the time of
kidney biopsy for the suspicion of glomerular disease. Of
these, 100 had IgA deposits in the mesangium, indicating IgA
nephritis, (P1–P100 in Supplementary Table I), and 92
patients (here designated “controls”) had other histological
patterns of glomerulonephritis (K1–K92). In addition, sera
from 20 age-matched healthy persons were included. All sera
were fractionated by affinity chromatography on immobilized
Fig. 3 Identification of major galectin-8N binding serum glycopro-
teins. a SDS-PAGE (4–20% stained with Coomassie) of galectin-8N
bound glycoproteins with major proteins indicated as previously
identified by Western blot and MALDI-TOF-MS [25]. b Estimated
relative amounts of galectin-8N bound serum proteins in four samples
by LC–MS/MS analysis of pooled tryptic peptides. The serum
concentrations of galectin-8N bound total protein and IgA were
determined by protein assay and nephelometry as given in Table SI.
The relative amounts of the remaining galectin-8N bound proteins
were determined by LC–MS/MS assuming a linear relationship
between sample protein concentration and the summed abundances
for the peptides uniquely mapping to each protein (Tables SII and
SIII). c SDS-PAGE of galectin-8N unbound (UB) and bound (B)
fractions with the highest protein concentrations from four healthy
individuals, four IgAN patients, and three controls with other
histological patterns of glomerulonephritis. Indicated to the left are
the mobilities of known size markers. The major visible bands of the
unbound fractions correspond to albumin (at 67 kDa), transferrin
(above the albumin), and IgG heavy chain (below the albumin)
250 J Clin Immunol (2012) 32:246–255galectin-8N as described above (Fig. 2). The yield of
galectin-8N-binding proteins from the IgAN sera was on
average 3.3 mg/ml (range 0.3–7.3), whereas the yields were
significantly (p<0.0001, one-sample t t e s t )l o w e rf o rt h es e r a
of the controls (2.2 mg/ml; range 0.9–5.5) and healthy
(2.1 mg/ml; range 0.8–4.1) (Fig. 4). Most of the increase of
galectin-8N-binding proteins in IgAN sera was not due to
IgA as described below, but in some cases due to haptoglobin
(as for sample P2, Fig. 3b, c), and/or other glycoproteins.
Significant Increase of Galectin-8 Non-binding
IgA in IgAN Patients
IgA levels were determined for all subjects, in unfractio-
nated sera (total IgA) and in the galectin-8N bound
fractions, and the difference gave galectin-8N unbound
IgA (Fig. 5). Total IgA content in 98 IgAN patient sera was
on average 3.4 mg/ml serum (range 1.5–7.7) compared to
2.3 (range 0.8–4.4) in 76 controls and 2.1 (range 0.1–4.3) in
17 healthy subjects (Fig. 5a). Most of this was due to
galectin-8N non-binding IgA, on average 2.6 mg/ml (range
0.4–7.0) in IgAN compared to 1.6 (range 0.4–3.5) in
controls and 1.5 mg (range 0.1–3.5) in healthy individuals
(Fig. 5b). In contrast, there was only a small difference in
the content of galectin-8N bound IgA between the subject
groups (not shown). Plotting the ratio of galectin-8N
bound/unbound IgA (Fig. 5c) revealed an interesting
stratification of the IgAN patients. For the major group
(patients), the ratio was similar as found for the controls
and healthy, but a smaller group (16 patients) had a much
lower ratio of galectin-8N bound/unbound IgA (<0.1), not
found for any of the healthy and only one of the controls. A
scatter plot of the ratio of galectin-8N bound/unbound IgA
(<0.1) vs. total IgA again revealed that most IgAN patients
fell in the same area as the healthy and controls (Fig. 5d).
However, 15 IgAN patients clearly fell outside this because
of the lower ratio and four additional ones because of
higher total IgA.
Relationship of Galectin-8N-Binding and Non-binding IgA
to Disease Progression and Other Parameters
in IgA Nephritis
When the time to end stage renal disease was plotted for 97
IgAN in a Kaplan–Meier type of graph (Fig. 6), there was a
trend for a relationship of a low ratio of galectin-8N bound/
unbound IgA (<0.5) to faster progress. However, the
difference to the comparison group (ratio >0.5) was not
significant (p∼0.06), possibly because the follow-up time
was somewhat limited for patients included in the last years
of the study. Similar comparisons against total galectin-8N
bound glycoprotein and total galectin-8N non-bound IgA
did not give significant relationships to disease progression.
The galectin-8-related parameters described here were also
compared to a number of other patients’ parameters
including serum initial and end creatinine, haptoglobin,
classification of IgA deposits, age, and gender, but no
significant correlations were found (not shown).
Discussion
In the present study, we found that the IgA in patients with
IgAN has reduced binding to galectin-8N and that this
decrease is associated with disease severity. We demon-
strate for the first time a clear difference in the binding
ability of normal and altered IgA of IgAN to an endogenous
lectin, galectin-8, suggesting a new type of functional
difference related to the glycosylation. Unexpectedly, we
also found that a higher proportion of other serum
glycoproteins from IgAN patients bind galectin-8N.
The binding of IgA to galectin-8N as measured by
affinity chromatography here requires a higher affinity than
Kd∼5 μM[ 25]. Here we show that this binding is restricted
to IgA1 and requires the presence of NeuAc; together with
known specificity of galectin-8N, this indicates that the
binding is mediated by the O-glycan NeuAcα2,3Galβ1,3-
GalNAc (the top glycan of Fig. 1), while the other O-
glycans would not bind as described in the “Introduction”.
Over 95% of the sialylated N-glycans would also not bind
because the NeuAc is linked to the sixth position of Gal
[35], which blocks binding of all galectins [22]. NeuA-
Fig. 4 Significant increase of serum proteins binding to galectin-8N
in IgAN patients. Yields of galectin-8N binding serum glycoproteins
(sum of amount in bound fractions multiplied by 10 to give milligram
per milliliter of original serum) for sera from 100 IgAN patients, 20
healthy subjects, and 92 controls with IgAN symptoms. Horizontal
lines mark the mean for each group (mean/median for each group (mg/
ml sera): 3.3/3.1, 2.2/2.1, 2.1/2.1); the difference between IgAN
patients and the two other groups was statistically significant (p<
0.0001) as calculated by one-way ANOVA. Yields from all sera are
found in supplementary Table I
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glycans on pooled healthy human serum IgA as estimated
by [35]. Galectin-8N selectively binds a fraction of serum
IgA (here on average 43% in healthy serum with the range
16–78%) containing this glycan, a feature that decreases in
the altered IgA of IgAN.
In contrast, other investigators have measured features
that increase in altered IgA in IgAN, mainly terminal
GalNAcα (second last structure of Fig. 1), as detected by
the binding of snail lectins [20, 36]. This gives a score for
the lectin binding, but no quantitation of the proportion of
IgA affected. The galectin-8N non-bound IgA measured
here and the snail lectin-binding IgA measured in other
studies probably represent overlapping fractions of the IgA,
but may not be completely identical. The degree of partial
segregation of IgAN patients from others based on both
total IgA (Fig. 5a) and galectin-8N non-binding IgA
(Fig. 5b) detected here is similar as found for total IgA
[4, 37] and snail lectin-binding IgA in other studies [21,
36]. In addition, we identified a subgroup of the IgAN
patients (about 15%) with particularly low ratio of galectin-
8N bound/unbound IgA not found for any of the healthy
and the kidney disease controls (Fig. 5c, d). In other
studies, this subgroup would have been included among the
subjects with increased GalNAcα (detected by snail lectin
binding), but could not have been detected separately.
The sera studied here were collected at the time of renal
biopsy, and there was no significant correlation with
clinical outcome at that time point and the amount or
proportion of unbound IgA. However, there was a trend for
a correlation with subsequent progression to end stage renal
disease and a low galectin-8N bound/unbound IgA ratio.
Even though the significance was weak (p=0.059, Fig. 6),
the finding is intriguing and stimulates further studies.
The galectin-8N-binding fraction of serum glycoproteins
other than IgA was unexpectedly significantly higher in the
IgAN cases compared to the healthy and kidney disease
Fig. 6 Indication of increased rate of disease progress to end stage renal
disease for IgAN patients with low galectin-8 bound/unbound IgA ratio.
Kaplan–Meiercumulativeanalysisofendstagerenaldiseasefor87IgAN
patients, divided according to the ratio of galectin-8N bound/unbound
IgAwith a cutoff at a ratio 0.50 based on the mean in the control group.
Patients with a ratio >0.50 may have better early (the first 9 years) renal
survival than patients with a binding ratio <0.50, although statistical
significance is slightly weaker than 0.05 level (p=0.059, log rank test).
Forty-one patients were lost from the follow-up group and are censored
as indicated by vertical lines
Fig. 5 Significant increase of galectin-8N non-binding IgA in sera
from IgAN patients compared to healthy controls. a Total IgA (mean/
median for each group (mg/ml sera): 3.4/3.3, 1,7/2.1, 2.3/2.4), b
galectin-8N unbound (total bound) IgA (mean/median for each group
(mg/ml sera): 2.6/2.4, 1.5/1.0, 1.6/1.7), and c ratio of galectin-8N
bound/unbound serum IgA (logarithmic scale on the Y-axis) in sera
from 98 IgAN patients, 17 healthy, and 76 kidney disease controls. d
Scatter plot of ratio from c (Y-axis) vs. total IgA (X-axis). IgA in
unfractionated serum (total) or galectin-8N bound fractions was
quantitated using nephelometry. Horizontal lines mark the average
for each group in a–c. The difference between groups was statistically
significant (p<0.0001) as calculated by one-way ANOVA
252 J Clin Immunol (2012) 32:246–255controls(Fig.4). This increase may be due to changes also in
N-glycans as some of the proteins affected, e.g., haptoglobin,
are not known to have O-glycans. Indeed, analyzing bound
fractions from two IgAN patients with reversed phase LC–
MS/MS revealed a large increase of bound haptoglobin in
one of the patients (sample P2 in Fig. 3b, c). Although this
protein is a likely candidate with known glycosylation
changes in pathological conditions [32], the serum from
other patients showed no increased levels of bound hapto-
globin but possibly an increase of several other proteins,
illustrating the complexity of the disease. One possible
change is increased levels of 2–3-sialylated galactosides
(NeuAcα2,3Galβ1-), a known but less common feature in
normal human serum N-glycans, recognized to bind galectin-
8N well [24]. This increase of galectin-8N-binding glyco-
proteins was neither seen for the kidney disease controls
(Fig. 4) nor for 25 breast cancer patients [32], suggesting a
relationship to IgAN. As for the changes in IgA described
above, there was no significant correlation with particular
disease parameters or progress of IgAN (not shown). Even if
the binding sites are found only in a low percentage of N-
glycans, they can result in binding of a high percentage of
proteins carrying many glycans [32]. This may explain why
the fraction of serum glycoproteins that bind galectin-8N is
relatively large—on average 15% of all after exclusion of
albumin, IgG, and IgA in healthy sera and on average 25%
in sera from IgAN patients with some as high as 60%,
suggesting that galectin-8 binding may represent a major
pathophysiological change in the disease condition.
At present, it is only possible to speculate about the
possible pathophysiological role of galectin-8 binding to IgA
and other serum glycoproteins. It is not likely to have much
effect in serum or plasma itself as there the concentration of
galectins(lownanomolarrange)isfarbelowtheconcentration
of the major bound glycoproteins. Instead, the functional role
is likely when the glycoprotein encounters cells where the
galectin is expressed. Galectin-8 has a wide expression in
different cells [38], with particularly high expression in
plasma cells [39] and lymphatic endothelial cells [40].
Moreover, high levels of galectin-8 have been found in
synovial fluid cells of rheumatoid arthritis patients [33], and
increased renal expression of other galectins has been found
in other forms of nephritis [41, 42]. A number of possible
cellular functions have been suggested for galectin-8. Roles
in cell adhesion of Jurkat T cells and regulation of cell
signaling by binding of glycoproteins have been proposed
[43], as well as promoting differentiation of mature B cells
into Ig-secreting plasma cells upon cell surface binding [39].
An emerging view is that galectins direct intracellular
trafficking of glycoproteins in cells [44, 45], either after
synthesis in the cell itself or after uptake by endocytosis as
recently shown by us for haptoglobin and galectin-1 [32].
Thus, galectin-8 binding to IgA could act either while it is
synthesized in plasma cells, or when it reassociates with cells
after circulation, e.g., in the kidney mesangium where IgA-
containing immune complexes deposit [46]. Recently, it has
been shown that surface-attached galectin-8 is exposed on
the membrane of thrombin-stimulated platelets [47] and that
increased expression of factor V, an upstream signal of
thrombin, causes the fibrin depositions connected to the
development IgAN [48]. It is feasible that there will be an
increased number of surface-exposed galectin-8 molecules in
fibrinogenic mesangiolytic lesions that could act as a root for
the formation of complexes. Our findings highlight the
potential prospect and importance in using widely expressed
endogenous lectins for detection of aberrantly glycosylated
IgA in IgA nephritis and should stimulate further studies on
the role of galectin-8 in the disease.
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